Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

The two-decade legal and business veteran joins Second Front from one of the national security software company's investors. Second Front Systems, a venture-backed developer of cloud-based ...

On the global front, trade tensions appear to be easing, as the European Union has delayed countermeasures on U.S. products until mid-April, giving extra time for discussions. Additionally ...

Regular readers know about Bertie’s skepticism when it comes to using low per capita consumption as an investment thesis to buy stocks. With 1.4 billion people in the denominator, the per-person ...

But then Trump's tariff plans have been playing spoilsport. What is your base case scenario as to how pharma exporters may get impacted? Indian companies play a crucial role in supplying high-quality ...

American pharmaceutical major Eli Lilly and Company on Thursday (March 20, 2025) launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in ...

This was the president of the United States doing the bidding of the pharmaceutical companies twice to ring his counterpart in Australia,” Robb says. “It just shows you how strong the ...

Anthony Scott is the Director of the Centre for Health Economics, which has a contract with the Department of Health and Aged Care to review evidence submitted by pharmaceutical companies for ...